Welcome to our dedicated page for CRY news (Ticker: CRY), a resource for investors and traders seeking the latest updates and insights on CRY stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CRY's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CRY's position in the market.
CryoLife, Inc. (NYSE: CRY), a leader in cardiac and vascular surgery, will participate in the UBS Global Healthcare Virtual Conference on May 25, 2021. The company's fireside chat is set for 11:00 a.m. ET. Investors can access a live webcast on CryoLife's website, along with an archived version available for 90 days post-event. Headquartered in Atlanta, CryoLife specializes in medical devices for aortic repair and has a global market presence in over 100 countries.
CryoLife, Inc. reported a 7% increase in total revenues, reaching $71.1 million for Q1 2021 compared to $66.4 million in Q1 2020. The company reported a net loss of $3.1 million, or $0.08 per share, an improvement from the $6.7 million loss in the previous year. Non-GAAP net income was $1.4 million, or $0.03 per share. Although COVID-19 continues to impact operations, growth was attributed to new product launches and a recovery in procedure volume. The company will not provide full-year guidance for 2021 due to pandemic uncertainties.
CryoLife, Inc. (NYSE: CRY) announced the release date for its first quarter 2021 financial results on April 29, 2021, after market close. A teleconference will follow at 4:30 p.m. ET hosted by CEO Pat Mackin. The call will include a question and answer session. Investors can access a replay from April 29 to May 6, 2021. CryoLife, a leader in cardiac and vascular surgery products, services over 100 countries worldwide. For more details, visit www.cryolife.com.
CryoLife, Inc. (NYSE: CRY), a prominent cardiac and vascular surgery company, will participate in the 20th Annual Needham Virtual Healthcare Conference on April 14, 2021, at 8:45 a.m. ET. The event will feature a virtual fireside chat, which can be accessed via the company's website on the Investor Relations page. An archived version of the chat will be available for 90 days post-event. Headquartered in Atlanta, Georgia, CryoLife specializes in medical devices and implantable tissues for aortic repair procedures.
CryoLife, a leader in cardiac and vascular surgery, will participate in the Oppenheimer 31st Annual Virtual Healthcare Conference on March 16-17, 2021. The company's fireside chat is set for 11:20 a.m. ET on March 16. A live webcast will be available on CryoLife's website, and an archived version will be accessible for 90 days post-event. Headquartered in Atlanta, Georgia, CryoLife specializes in medical devices for aortic repair and distributes its products in over 100 countries.
CryoLife reported fourth quarter 2020 revenues of $67.9 million, down 3% from $69.7 million in Q4 2019.
Net loss reached ($3.5 million) or ($0.09) per share, compared to a loss of ($0.7 million) in Q4 2019.
For the full year, total revenues were $253.2 million, an 8% decline from 2019.
Non-GAAP net income for Q4 was $7.9 million or $0.20 per share, up from $4.2 million in Q4 2019. The company refrained from issuing 2021 guidance due to ongoing COVID-19 uncertainties.
CryoLife, Inc. (NYSE: CRY) announced the release date for its fourth quarter and full year 2020 financial results, set for February 11, 2021, after market closure. A teleconference call will follow at 4:30 p.m. ET, led by Pat Mackin, Chairman and CEO. Investors can participate by calling 201-689-8261. Replay will be available from February 11 to 18, 2021. The financial results will be accessible on the CryoLife website in the Investor Relations section.
CryoLife, Inc. (NYSE: CRY) will host a webcast on December 7, 2020, at 4:00 p.m. EST, to discuss progress in its PROACT Xa clinical trial. This randomized trial examines the safety and efficacy of apixaban versus warfarin for patients with On-X mechanical aortic valves. Enrollment began earlier this year, targeting around 1,000 participants across 60 sites. The trial’s primary endpoints focus on valve thrombosis and safety outcomes. The aortic surgical valve market is valued at approximately $1.2 billion.
CryoLife reported total revenues of $65.1 million for Q3 2020, a 4% decline compared to Q3 2019. The company posted a net loss of ($2.9 million) or ($0.08 per share, while non-GAAP net income rose to $4.9 million, $0.13 per share. The decline was attributed to the impact of the COVID-19 pandemic on procedures. Despite these challenges, the company completed the acquisition of Ascyrus Medical LLC, enhancing its product offerings and increasing the addressable market to over $6 billion. No 2020 financial guidance was issued due to ongoing uncertainties.
CryoLife, Inc. (NYSE: CRY) will announce its 2020 third quarter financial results on November 4, 2020, after market close. A teleconference will be held at 4:30 p.m. ET to discuss these results, led by CEO Pat Mackin, followed by a Q&A session. Interested parties can join via phone or access the live webcast on the company's website. A replay will be available until November 11, 2020. CryoLife specializes in medical devices for cardiac and vascular procedures and markets its products in over 100 countries.
